---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349197"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2026-08-13T20:11:12+00:00"
generated_at: "2026-08-13T20:13:20.626359+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q2 2026 net loss $8.4M; RT-114 oral bioavailability >150% vs subcutaneous

## Summary
- RT-114 Phase 1a: oral bioavailability >150% vs matched subcutaneous PG-102; no serious adverse events.
- First participants dosed in Phase 1a expansion cohort; Phase 1b in obesity expected by end 2026.
- Completed $20M registered direct offering; cash $53.4M as of June 30, 2026, sufficient through 2027.
- New PegBio collaboration to explore oral delivery of obesity/metabolic molecules via RaniPill.
- Appointed Nicholas Maestas as CFO and Michelle Gilson to Board; net loss $8.4M vs $11.2M YoY.

## SEC filing metadata
- accession: 0001193125-26-349197
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2026-08-13T20:11:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/0001193125-26-349197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349197
- JSON: https://secwatch.observer/filing/0001193125-26-349197.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.